Galectin Therapeutics, Inc. (GALT)
3.94
+0.30
(+8.24%)
USD |
NASDAQ |
Oct 09, 16:00
3.925
-0.02
(-0.38%)
After-Hours: 20:00
Galectin Therapeutics Cash from Operations (Quarterly) : -2.439M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.439M |
| March 31, 2026 | -3.866M |
| December 31, 2025 | -6.042M |
| September 30, 2025 | -3.542M |
| June 30, 2025 | -6.602M |
| March 31, 2025 | -7.689M |
| December 31, 2024 | -12.79M |
| September 30, 2024 | -8.538M |
| June 30, 2024 | -8.333M |
| March 31, 2024 | -12.10M |
| December 31, 2023 | -4.702M |
| September 30, 2023 | -7.637M |
| June 30, 2023 | -9.833M |
| March 31, 2023 | -10.79M |
| December 31, 2022 | -7.239M |
| September 30, 2022 | -8.347M |
| June 30, 2022 | -7.428M |
| March 31, 2022 | -8.042M |
| December 31, 2021 | -6.951M |
| September 30, 2021 | -4.998M |
| June 30, 2021 | -5.977M |
| March 31, 2021 | -6.382M |
| December 31, 2020 | -5.414M |
| September 30, 2020 | -8.212M |
| June 30, 2020 | -2.604M |
| Date | Value |
|---|---|
| March 31, 2020 | -4.371M |
| December 31, 2019 | -3.759M |
| September 30, 2019 | -1.475M |
| June 30, 2019 | -2.33M |
| March 31, 2019 | -3.284M |
| December 31, 2018 | -2.007M |
| September 30, 2018 | -1.577M |
| June 30, 2018 | -3.079M |
| March 31, 2018 | -3.516M |
| December 31, 2017 | -3.904M |
| September 30, 2017 | -3.123M |
| June 30, 2017 | -5.002M |
| March 31, 2017 | -3.863M |
| December 31, 2016 | -4.865M |
| September 30, 2016 | -3.444M |
| June 30, 2016 | -4.61M |
| March 31, 2016 | -3.49M |
| December 31, 2015 | -4.601M |
| September 30, 2015 | -5.084M |
| June 30, 2015 | -2.987M |
| March 31, 2015 | -4.311M |
| December 31, 2014 | -3.113M |
| September 30, 2014 | -3.282M |
| June 30, 2014 | -2.412M |
| March 31, 2014 | -3.619M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Mirum Pharmaceuticals, Inc. | -44.25M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 1.597M |
| Free Cash Flow | -15.89M |
| Free Cash Flow Per Share (Quarterly) | -0.037 |
| Free Cash Flow to Equity (Quarterly) | -4.484M |
| Free Cash Flow to Firm (Quarterly) | -0.435M |
| Free Cash Flow Yield | -6.18% |